Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Cell Cycle/DNA Damage

Chemical Structure Cat. No. Product Name CAS No.
TP1287 Chemical Structure
BCP49599 TP1287 2044686-42-0
TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active CDK9 inhibitor.
Sudocetaxel Zendusortide Chemical Structure
BCP49436 Sudocetaxel Zendusortide 2473125-34-5
Sudocetaxel Zendusortide is a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers.
HC-5404 Chemical Structure
BCP49422 HC-5404 HC-5404
HC-5404 is a differentiated, orally bioavailable investigational small molecule inhibitor of PERK (PKR-like endoplasmic reticulum kinase).
Saroglitazar magnesium Chemical Structure
BCP49279 Saroglitazar magnesium 1639792-20-3
Saroglitazar magnesium is a dual agonist at the PPARα and PPARγ of the peroxisome proliferator-activated receptor (PPAR).
Irinotecan sucrosofate Chemical Structure
BCP49278 Irinotecan sucrosofate 1361317-83-0
Irinotecan is a camptothecin analog and topoisomerase I inhibitor.
Onvansertib fumarate Chemical Structure
BCP49273 Onvansertib fumarate 1263293-37-3
Onvansertib fumarate is a A polo-like kinase 1 inhibitor, an antineoplastic.
Bocidelpar hemisulfate Chemical Structure
BCP49259 Bocidelpar hemisulfate BH
Bocidelpar, also known as ASP0367 or MA-0211, is a peroxisome proliferator-activated receptor (PPAR) delta agonist.
Bocidelpar sulfate Chemical Structure
BCP49258 Bocidelpar sulfate 2095128-21-3
Bocidelpar is a peroxisome proliferator-activated receptor (PPAR) delta agonist.
Mavodelpar sodium Chemical Structure
BCP49236 Mavodelpar sodium 1604815-32-8
Mavodelpar is a selective PPARδ agonist.
ARX-788 Chemical Structure
BCP49232 ARX-788 2636710-07-9
ARX788 is a next-generation, site-specific anti-HER2 ADC that utilizes a unique nonnatural amino acid–enabled conjugation technology and a noncleavable Amberstatin (AS269) drug-linker to generate a homogeneous ADC with a drug-to-antibody ratio of 1.9.
123下一页末页共 1217 条记录 1 / 122 页 
0086-13720134139